FIELD: biotechnology.
SUBSTANCE: group of inventions refers to an anti-PD1 monoclonal antibody or antigen-binding fragment thereof, wherein said antibody comprises a heavy chain variable region, comprising SEQ ID NO: 1 (heavy chain CDR1), SEQ ID NO: 2 (heavy chain CDR2), SEQ ID NO: 3 (heavy chain CDR3), and a light chain variable region comprising SEQ ID NO: 4 (light chain CDR1), SEQ ID NO: 5 (light chain CDR2) and SEQ ID NO: 6 (light chain CDR3). Group of inventions also relates to an isolated nucleic acid molecule encoding said antibody; an expression vector; a method for modulating an immune response in a subject comprising administering to said subject an antibody; use of said antibody or its antigen-binding fragment in producing a drug for inhibiting growth of tumor cells in a subject.
EFFECT: group of inventions provides high affinity for PD1 and thermal stability of the antibody.
16 cl, 20 ex, 14 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2494107C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2406760C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO GD2 (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2796937C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
